PressJuly 31, 2023 COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
PressJuly 28, 2023 Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
PressJuly 28, 2023 Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
PressJuly 28, 2023 Mind Cure Announces LNG Energy Group Credit Agreement in the Amount of U.S. $70 Million to Acquire Lewis Energy Colombia, Inc.
PressJuly 25, 2023 PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
PressJuly 25, 2023 First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
PressJuly 25, 2023 Filament Health Announces Upsizing and Closing of $2,500,000 Non-Brokered Private Placement Financing
PressJuly 21, 2023 PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
PressJuly 20, 2023 Kernel’s Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects
PressJuly 20, 2023 Filament Health Corp. To List on Nasdaq Through Business Combination With Jupiter Acquisition Corporation
PressJuly 20, 2023 Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
PressJuly 20, 2023 Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast
PressJuly 20, 2023 Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
PressJuly 20, 2023 PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
PressJuly 20, 2023 Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering of Up To C$2,000,000
PressJuly 18, 2023 PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
PressJuly 17, 2023 Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
PressJuly 17, 2023 COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
